OOIR: Observatory of International Research

Papers

(The TQCC of Experimental Hematology & Oncology is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Construction and characterization of chimeric FcγR T cells for universal T cell therapy	132
Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics	129
Suppression of CYLD by HER3 confers ovarian cancer platinum resistance via inhibiting apoptosis and by inducing drug efflux	114
Cell membrane patches transfer CAR molecules from a cellular depot to conventional T cells for constructing innovative fused-CAR-T cells without necessitating genetic modification	107
The roles of tissue resident macrophages in health and cancer	95
ProNGF promotes brain metastasis through TrkA/EphA2 induced Src activation in triple negative breast cancer cells	91
Allogeneic stem cell transplantation may overcome the adverse impact of myelofibrosis on the prognosis of myelodysplastic syndrome	74
Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancers	70
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting	61
Metastatic clear-cell renal cell carcinoma: a frequent NOTCH1 mutation predictive of response to anti-NOTCH1 CB-103 treatment	58
The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling	56
ASAP2 interrupts c-MET-CIN85 interaction to sustain HGF/c-MET-induced malignant potentials in hepatocellular carcinoma	55
Age-related accumulation of B-1 cell progenitors in mice reflects changes in miR15a/16-1 expression and radioresistance capacity	52
Sphingosine kinase 1 contributes to the metastatic potential of epithelial ovarian cancer to the adipocyte-rich niche	47
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera	47
Mutational signatures of synchronous and metachronous brain metastases from lung adenocarcinoma	46
Ubiquitin-specific protease 28: the decipherment of its dual roles in cancer development	45
CD44 promotes hepatocellular carcinoma progression via upregulation of YAP	45
Spliceosome inhibitor induces human hematopoietic progenitor cell reprogramming toward stemness	45
Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside	45
DLC1 deficiency at diagnosis predicts poor prognosis in acute myeloid leukemia	45
Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials	44
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting	42
A bile-based microRNA signature for differentiating malignant from benign pancreaticobiliary disease	42
CRISPR/Cas9-mediated knockout of intracellular molecule SHP-1 enhances tumor-killing ability of CD133-targeted CAR T cells in vitro	40

CUL4A-DDB1-circRFWD2 E3 ligase complex mediates the ubiquitination of p27 to promote multiple myeloma proliferation	39
cGAS-ISG15-RAGE axis reprogram necroptotic microenvironment and promote lymphatic metastasis in head and neck cancer	39
Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation	38
Identifying ADGRG1 as a specific marker for tumor-reactive T cells in acute myeloid leukemia	37
Prospective pharmacotyping of urothelial carcinoma organoids for drug sensitivity prediction – feasibility and real world experience	34
Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies	33
Correction: ScRNA-seq revealed an immunosuppression state and tumor microenvironment heterogeneity related to lymph node metastasis in prostate cancer	33
Single-cell analysis defines highly specific leukemia-induced neutrophils and links MMP8 expression to recruitment of tumor associated neutrophils during FGFR1 driven leukemogenesis	33
Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling	33
Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting	32
The role of pyroptosis and gasdermin family in tumor progression and immune microenvironment	31
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives	30
Efficacy and safety of immune checkpoint inhibitors in metastatic penile squamous cell carcinoma: a retrospective multicenter analysis	30
Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development	30
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review	29
A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy	27
Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target	27
CircFBXW7 in patients with T-cell ALL: depletion sustains MYC and NOTCH activation and leukemia cell viability	27
Targeting the integrated stress response in hematologic malignancies	27
TRIM family contribute to tumorigenesis, cancer development, and drug resistance	26
Focal adhesion kinase: from biological functions to therapeutic strategies	26
New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	26
Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy	26
Surface TREM2 on circulating M-MDSCs as a novel prognostic factor for adults with treatment-naïve diffuse large B-cell lymphoma	25
Chimeric antigen receptor engineered natural killer cells for cancer therapy	25
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD	25
Targeting hepcidin in colorectal cancer triggers a TNF-dependent-gasdermin E-driven immunogenic cell death response	24
Targeting and cytotoxicity of chimeric antigen receptor T cells grafted with PD1 extramembrane domain	24
ALKBH5 prevents hepatocellular carcinoma progression by post-transcriptional inhibition of PAQR4 in an m6A dependent manner	24
Lactylation modification in cancer: mechanisms, functions, and therapeutic strategies	23
CAR-T cell combination therapies in hematologic malignancies	23
Ibrutinib and acalabrutinib use and risk of incident atrial fibrillation: a propensity-matched analysis	23
A proinflammatory response and polarized differentiation of stromal elements characterizes the murine myeloma bone marrow niche	23
Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities	22
Correction: New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	22
HIV associated lymphoma: latest updates from 2023 ASH annual meeting	22
Correction: Breast cancer heterogeneity and its implication in personalized precision therapy	22
A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases	22
Recent updates on central nervous system prophylaxis in patients with high-risk diffuse large B-cell lymphoma	21
Enhanced cellular therapy: revolutionizing adoptive cellular therapy	21
Transfer RNA-derived small RNA: an emerging small non-coding RNA with key roles in cancer	20
Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis	20
All-in-one CRISPR/Cas-engineered glucocorticoid-receptor knock-out EBV-gp350-CAR knock-in T cells are potent and resistant to dexamethasone	20
1q jumping translocation as a biomarker in myeloid malignancy: frequently mutated genes associated with bad prognosis and low survival	20
Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA	20
Function and clinical significance of N6-methyladenosine in digestive system tumours	20
COVID-19 vaccination associated severe immune thrombocytopenia	19
Biomechanics in the tumor microenvironment: from biological functions to potential clinical applications	19
GPR68-ATF4 signaling is a novel prosurvival pathway in glioblastoma activated by acidic extracellular microenvironment	19
Correction: Unraveling the structures, functions and mechanisms of epithelial membrane protein family in human cancers	19

Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas	18
MSCsDB: a database of single-cell transcriptomic profiles and in-depth comprehensive analyses of human mesenchymal stem cells	18
Progression patterns in monoclonal gammopathy of undetermined significance and multiple myeloma outcome: a cohort study in 42 patients	18
Genome-wide CRISPR/Cas9 library screening identified ATM signaling network genes as critical drivers for resistance to ATR inhibition in soft-tissue sarcomas: synthetic lethality and therapeutic impli	18
Platelet-driven coagulopathy in COVID-19 patients: in comparison to seasonal influenza cases	18
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors	17
HOXA13 promotes gastric cancer progression partially via the FN1-mediated FAK/Src axis	17
Cell competition between wild-type and JAK2V617F mutant cells prevents disease relapse after stem cell transplantation in a murine model of myeloproliferative neoplasm	17
Multi-omic profiling of the leukemic microenvironment shows bone marrow interstitial fluid is distinct from peripheral blood plasma	17
RNA sequencing identifies novel regulated IRE1-dependent decay targets that affect multiple myeloma survival and proliferation	17
GPR109A controls neutrophil extracellular traps formation and improve early sepsis by regulating ROS/PAD4/Cit-H3 signal axis	16
Adefovir dipivoxil inhibits APL progression through degradation of the oncoprotein PML-RARA	16
CTP synthase 2 predicts inferior survival and mediates DNA damage response via interacting with BRCA1 in chronic lymphocytic leukemia	16
CircRIC8B regulates the lipid metabolism of chronic lymphocytic leukemia through miR199b-5p/LPL axis	16
Alpha-B-Crystallin overexpression is sufficient to promote tumorigenesis and metastasis in mice	15
LINP1 represses unfolded protein response by directly inhibiting eIF2α phosphorylation to promote cutaneous squamous cell carcinoma	15
ANXA6/TRPV2 axis promotes lymphatic metastasis in head and neck squamous cell carcinoma by inducing autophagy	15
Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer	15
Roles of N6-methyladenosine (m6A) modifications in gynecologic cancers: mechanisms and therapeutic targeting	15
Molecular characterization of the CXCR4 / CXCR7 axis in germ cell tumors and its targetability using nanobody-drug-conjugates	15
Secretogranin II influences the assembly and function of MHC class I in melanoma	14
NK cell transfer overcomes resistance to PD-(L)1 therapy in aged mice	14
Combination of percutaneous thermal ablation and adoptive Th9 cell transfer therapy against non-small cell lung cancer	14
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma	14
Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy	14
Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies	13
Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies	13
Decoding leukemia at the single-cell level: clonal architecture, classification, microenvironment, and drug resistance	13
Analysis of CD20 and PD-L1 levels on small extracellular vesicles (sEV) produced by DLBCL cells and EBV-transformed B cells, and potential role in T cell inhibition	13
Nuclear porcupine mediates XRCC6/Ku70 S-palmitoylation in the DNA damage response	13
The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma	13